Can We Trust Psychedelic Studies?

Welcome to this week's edition of the PSYCHSPACE Newsletter!

🌌 Embark on a journey through the psychedelic realm where we bring you the latest scoop, blending insights with a dash of humor. From scientific snags to business booms, we've got the highlights to keep your knowledge trip as enlightening as it is enjoyable.

Stay tuned and keep your minds open as we continue to explore the ever-expanding universe of psychedelics. Catch you on the next wave!

📚 This Week's Highlights:

Media/News: 📰 Research Rumble: Dive into the debate as psychedelic studies hit a hiccup. The call for tighter protocols isn't just academic nitpicking—it's about steering the ship through stormy seas to the shores of solid science.

Research: 🌐 Vancouver's Visionary Voyage: Watch as Filament Health's PEX010 sets sail from Vancouver to international waters, aiming to anchor psychedelic therapy in the bay of mainstream medicine.

Business: 💸 Cybin's Cash Catalyst: Cybin Inc. is riding high on a $150M wave of investment, propelling its psilocybin crusade into the future.

A recent concern for current research methodologies in psychedelic studies raises worry in researchers. From the get-go, the study critiques uneven psychological support across trials and a pick-and-choose approach to participant selection.

It’s a wake-up call for the psychonauts and scientists alike: to steer the ship right, we need tighter protocols and a bigger welcome mat.

The goal?

To ensure the groundbreaking potential of psychedelics isn’t just a trip of fancy but a journey to better mental health solutions.

In a quirky twist from the norm, a book on psychedelics, overdue for 37 years, made its way back to a library, accompanied by a mysterious note. The note apologized for the "long, strange trip" the book had been on, adding an ironic touch to the late return.

This incident reflects the reality of forgetting something along the way, it happens. All the while, a funny way to reignite some good ol’ psychedelic energy.

Vancouver's Filament Health is spreading its roots far and wide, shipping its botanical psilocybin drug contender, PEX010, across four countries for a psychedelic showdown in mental health.

From tackling depression to reining in cannabis use, this globetrotting psilocybin candidate is set to dance through hoops of international trials, including a spotlight at Johns Hopkins.

With 30 trials lighting the way, Filament's trailblazing path could just be the trip mental health research needs.

Toronto's own Cybin Inc. is on a financial high, netting a cool $150 million in a private placement that's got the biotech world buzzing.

Backed by heavyweight investors, Cybin's eyeing the finish line for its groundbreaking psilocybin-based treatment, CYB003, aimed at tackling Major Depressive Disorder.

It's a major nod to the potential psychedelics hold in redefining mental health care. With a war chest now ready for Phase 3 trials, Cybin's journey from research to relief is one we're watching with bated breath.

Happy Caps is mushrooming across Canada, doubling its retail presence overnight to a whopping 270 stores. These aren't your average fungi; we're talking Shiitake, Lion's Mane, and Oyster mushrooms you can grow right on your kitchen counter.

Thanks to a partnership with Van Noorts, these kits are sprouting up everywhere from boutique health stores to major retail chains, proving that when it comes to wellness, Canadians are ready to grow their own.